Insurer Suits Take Aim at ‘Pay for Delay,’ Copay Assistance

In recently filed lawsuits, major health insurers accuse pharmaceutical companies of engaging in behavior that illegally boosted sales of their products. However, the alleged schemes are very different both in terms of how they work and whether policymakers are likely to step in and definitively end the practices, experts tell AIS Health.

Two of the lawsuits concern “pay-for-delay” deals, in which drug manufacturers sidestep competition for their branded products by offering patent settlements that effectively pay generic manufacturers not to bring their products to market. Humana Inc. and Centene Corp., in separate lawsuits filed in New Jersey’s District Court on Sept. 22, accuse Merck & Co., Inc. of using such a tactic when conspiring with generic manufacturers to delay the market entry of generic substitutes for two blockbuster cholesterol drugs, Vytorin and Zetia.

0 Comments
© 2022 MMIT
Leslie Small

Leslie Small

Leslie has been reporting and editing in various journalism roles for nearly a decade. Most recently, she was the senior editor of FierceHealthPayer, an e-newsletter covering the health insurance industry. A graduate of Penn State University, she previously served in editing roles at newspapers in Pennsylvania, Virginia and Colorado.

Related Posts

person-holding-a-pencil
September 30

Medicaid Plans Aren’t Properly Reporting MLR Data, OIG Finds

READ MORE
stethoscope-bill-and-pills
September 30

How Would Adjusting the Marketplace Coverage Benchmark to a Gold Plan Affect Affordability?

READ MORE
department-of-justice-building
September 30

Loss in UnitedHealth/Change Trial May Not Lower DOJ’s Deal-Blocking Appetite

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today